TV Host Promotes Bronchiectasis Awareness
Insmed Inc has partnered with TV host Ty Pennington to launch "Suspect Bronchiectasis (Suspect BE)," an educational initiative aimed at increasing awareness and proper diagnosis of bronchiectasis.
Tag: Insmed Inc
All
Latest
TV Host Promotes Bronchiectasis Awareness
Insmed Inc has partnered with TV host Ty Pennington to launch “Suspect Bronchiectasis (Suspect BE),” an educational initiative aimed at increasing awareness and proper diagnosis of bronchiectasis.
Read More
Positive Ph3 Arikayce Data for MAC Lung Disease
The ENCORE study showed that adding an inhaled amikacin suspension to multidrug therapy improved respiratory symptoms and increased culture conversion rates.
Read More
Insmed Presents Data on TPIP Inhalation Drug for PAH
Insmed will present four abstracts on treprostinil palmitil inhalation powder (TPIP), being evaluated as a once-daily therapy for the treatment of patients with PAH, PH-ILD, and other rare and serious pulmonary disorders.
Read More
European Commission Approves Brinsupri for Non-CF Bronchiectasis
Brinsupri (brensocatib) is now the first and only authorized treatment for non-cystic fibrosis bronchiectasis in the EU for patients 12 and older with recurrent exacerbations.
Read More
Brensocatib Reduced Bronchiectasis Exacerbations, Improved Symptoms in Asian Patients
The phase 3 ASPEN trial revealed brensocatib 10 mg and 25 mg significantly reduced bronchiectasis exacerbations, prolonged time to first exacerbation, and improved quality-of-life scores.
Read More
FDA Approves Brensocatib (Brinsupri) for Non-Cystic Fibrosis Bronchiectasis
Insmed’s Brinsupri (brensocatib) has been approved by the FDA as an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older.
Read More